Equity trader on Orphazyme surprise: "It's a bit like Gamestop all over again"

Orphazyme's share price has taken a wild ride over the past day – both in the US and Denmark. According to Mads Zink, head of Danish Cash Equities at Danske Bank, a Gamestop effect is happening.

Photo: Jens Dresling

Orphazyme trended on social media in the US on Thursday as its share price rocketed for no clear reason.

The biotech company has also attracted attention in Denmark, where the share price rose by 40 percent up to DKK 47.6 on Friday – a significant increase, but far less than the rise in the US.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Orphazyme cuts guidance following FDA setback

Friday's disappointing rejection letter from the US FDA is affecting Orphazyme's guidance for 2021. Now, the biotech firm forecasts an operating deficit of DKK 670-700m, up from DKK 100-150m.

Further reading

Related articles

Latest news

See all jobs